According to research, patients taking efgartigimod, a medication being tested for use in the treatment of chronic primary immune thrombocytopenia (ITP), showed a significantly greater improvement in platelet counts, which are necessary for clotting and stopping bleeding, compared to those taking a placebo.
Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.
Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.
DCGI has already given emergency use authorization (EUA) to BBIL for the intranasal vaccine. BBIL had in September this year applied for DCGI's approval for market authorization of its "Five Arms" intranasal heterologous booster dose, and it has now announced that iNCOVACC (BBV154) has received approval under Restricted Use in Emergency Situation for ages 18 and above.
New Delhi [India], September 11 (ANI): Bharat Biotech has applied for market authorisation from the Drugs Controller General of India (DCGI) for intranasal heterologous booster, sources told ANI.
New Delhi [India], September 6 (ANI): The Drugs Controller General of India (DCGI) rendered an emergency use authorization (EUA) to Bharat Biotech for the intranasal vaccine- iNCOVACC, said officials on Tuesday.
Hyderabad (Telangana) [India] September 1 (ANI): Hyderabad-based vaccines manufacturer Biological E Limited announced on Thursday that the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) reviewed and approved the Phase III infants clinical trial data and recommended for the manufacture of its 14-valent paediatric vaccine (investigational pneumococcal polysaccharide conjugate vaccine PCV14) against S pneumoniae infection in a single dose and multi-dose presentations.
Washington [US], July 16 (ANI): Strong protection against the SARS-CoV-2 virus with vaccination is short-lived and dependable protection against reinfection requires up-to-date boosters with vaccines that are adapted to address changes in the virus that occur as part of its natural evolution over time, says a new study.
Washington [US], June 13 (ANI): A subtle molecular change allows immunoglobulin to take on an expanded protective role during pregnancy, according to a study by the Cincinnati Children's Hospital Medical Center.
New Delhi [India], January 26 (ANI): The latest study conducted by Indian Council of Medical Research (ICMR) shows that antibodies generated by Omicron, a COVID-19 strain, are not only effective against it but also other variants of concern (VOCs) including Delta.
\
\
\
\
\
\
\
\
\
\
\
\
\
\
\
\
\
\
